Physician profile
Majd Issa
NPI 1548558034
$5,921.07
in general payments reported to CMS, 2019-2025
57 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.15 · 2023: $1,228 · 2024: $2,517 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,571 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,571.30 |
| Education | $333.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $550.84 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $451.62 | 2024-2025 | Reblozyl, Opdivo |
| Novartis Pharmaceuticals Corporation | $403.27 | 2023-2025 | |
| Janssen Biotech, INC. | $368.79 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Astellas Pharma US INC | $352.56 | 2023-2024 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $335.98 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Beigene USA, INC. | $282.83 | 2023-2024 | Brukinsa |
| Incyte Corporation | $271.64 | 2023-2025 | Pemazyre, Jakafi, Monjuvi |
| Daiichi Sankyo INC. | $196.54 | 2023-2025 | Enhertu, Injectafer |
| Abbvie INC. | $171.32 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.48 | 2024-2025 | Iclusig, Alunbrig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $154.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $148.49 | 2024-2025 | Calquence, Lynparza, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $134.88 | 2024-2025 | Libtayo, Lynozyfic |
| Kite Pharma, INC. | $117.07 | 2025 | Yescarta |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $110.48 | 2023-2025 | |
| Adc Therapeutics America, INC. | $94.28 | 2023-2024 | |
| Foundation Medicine, INC. | $91.77 | 2023 | |
| Eisai INC. | $80.50 | 2024 | |
| Servier Pharmaceuticals LLC | $78.91 | 2023-2025 | |
| Geron Corporation | $69.32 | 2025 | Rytelo |
| Emd Serono, INC. | $67.38 | 2024-2025 | |
| Sobi, INC | $64.55 | 2025 | |
| Genmab U.S., INC. | $64.07 | 2024 | Epkinly |
| Array Biopharma INC | $62.57 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Adaptive Biotechnologies Corporation | $58.99 | 2024-2025 | Clonoseq |
| Celgene Corporation | $58.36 | 2024 | Reblozyl, Pomalyst |
| Janssen Pharmaceuticals, INC | $55.04 | 2024-2025 | Xarelto |
| Puma Biotechnology, INC. | $54.85 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $47.11 | 2023-2024 | Provenge |
| Lilly USA, LLC | $45.44 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $44.36 | 2024 | Krazati |
| Spectrum Pharmaceuticals INC. | $44.10 | 2024-2025 | Rolvedon |
| Ipsen Biopharmaceuticals, INC | $40.31 | 2024 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $38.69 | 2024 | Venclexta, Columvi, Lunsumio |
| Alnylam Pharmaceuticals INC. | $33.11 | 2024 | Givlaari |
| Tersera Therapeutics LLC | $30.79 | 2023-2025 | Quzyttir, Xermelo |
| Lundbeck LLC | $30.17 | 2024 | Vyepti |
| Iovance Biotherapeutics, INC. | $30.13 | 2025 | Amtagvi |
| Tempus Ai, INC | $29.58 | 2025 | Xt Cdx |
| Kyowa Kirin, INC. | $29.27 | 2025 | |
| Stemline Therapeutics INC. | $27.70 | 2023 | Orserdu |
| Immunogen, INC. | $27.65 | 2023 | Elahere |
| Blueprint Medicines Corporation | $26.44 | 2024 | Ayvakit |
| Seagen INC. | $26.42 | 2023 | Tivdak |
| Legend Biotech USA INC. | $26.19 | 2025 | Carvykti |
| Gilead Sciences, INC. | $25.96 | 2024 | |
| Caris Mpi, INC. | $24.70 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $24.63 | 2025 | Brukinsa |
| Accord Healthcare, INC. | $22.87 | 2024 | |
| Deciphera Pharmaceuticals INC. | $22.83 | 2025 | Qinlock, Romvimza |
| Agios Pharmaceuticals, INC. | $21.47 | 2024 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $19.73 | 2024 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $19.04 | 2023 | Epkinly, Imbruvica |
| Amgen INC. | $16.15 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.84 | 2024 | Vivimusta |
| Alexion Pharmaceuticals, INC. | $14.46 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majd Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.